A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Year: 2025
Type: article
Abstract: Plain Language SummaryWhat is this summary about?This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma.What were the results?More participants in the COMBO group were alive for longer and without their disease getting worse after 7 years than those in the VEMU group.Among participants who switched to a new anticancer treatment, those in the COMBO group lived longer than those in the VEMU or ENCO groups.What do the results of the study mean?This confirms that people with BRAF V600-mutant melanoma treated with encorafenib plus binimetinib or encorafenib alone lived longer than those treated with vemurafenib.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Source: Future Oncology
Authors: Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Liszkay Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, Paola Queirolo, Carolin Guenzel, Anna Polli, Mahgull Thakur, Alessandra di Pietro, Paolo A Ascierto
Institutions: Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen, University Hospital Zurich, Massachusetts General Hospital, Université Paris-Saclay, Institut Gustave Roussy, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Isala, Universitätsklinikum Tübingen, National and Kapodistrian University of Athens, Medizinische Hochschule Hannover, Ruhr University Bochum, National Institute of Oncology, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, University of Perugia, National Cancer Centre Japan, European Institute of Oncology, Pfizer (United States), Pfizer (Italy), Pfizer (United Kingdom), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Funder: Pfizer
OpenAlex ID: W4406404890